Hyperammonemia, a condition marked by dangerously elevated ammonia levels in the blood, continues to draw attention from drug developers, healthcare systems, and investors alike. Rooted largely in urea cycle disorders and related metabolic conditions, hyperammonemia can lead to severe neurological complications if left untreated, making early diagnosis and effective therapy critical. According to recent Hyperammonemia…

Erdheim-Chester Disease (ECD) is a rare, non-Langerhans cell histiocytosis marked by the abnormal buildup of histiocytes in bone and soft tissue. Because it affects only a small number of patients worldwide, the disease has long been under-researched, but growing awareness among clinicians and a wave of new therapeutic candidates are reshaping how the condition is…

Heart failure remains one of the most stubborn challenges in modern medicine, and for patients whose own hearts can no longer keep them alive, a fully mechanical replacement can be the only option left. This is the world of total artificial heart technology — devices built to take over the work of both failing ventricles…

The REM sleep behavior disorder space is drawing growing attention from drugmakers and researchers, largely because the condition is now understood as more than just a sleep problem — it is increasingly viewed as an early warning sign of serious neurodegenerative disease. The REM sleep behavior disorder market is projected to expand at a meaningful…

Substance use disorders remain one of the most persistent public health challenges across the globe, and opioid-related dependence continues to draw significant attention from researchers, healthcare providers, and pharmaceutical developers alike. A recent industry report from DelveInsight offers a comprehensive look into the opium addiction market, covering historical and forecasted trends across the United States,…

Eisenmenger Complex is a severe, long-term consequence of congenital heart defects that go untreated for years, eventually causing pulmonary hypertension and a reversal of blood flow that sends oxygen-poor blood throughout the body. The condition brings cyanosis, fatigue, breathlessness, and multi-organ strain, and because it stems from decades of unmanaged heart abnormalities, the surrounding treatment…

Fractures don’t always heal on their own — and that simple fact is quietly building a substantial industry. The Bone Growth Stimulators Market stood at USD 1,337.03 million in 2024 and is on track to nearly reach USD 2,021.13 million by 2032, growing at a CAGR of 5.34% over the forecast window. Behind that trajectory…

Rare disease markets rarely stay quiet for long, and Acute Intermittent Porphyria (AIP) is a good example. Earlier genetic diagnosis, a new generation of RNA interference drugs, and friendlier regulatory pathways are all converging at once — and together they’re pushing the Porphyria Market toward a steady growth curve between 2025 and 2034. What Is…

The chondrosarcoma market is entering a pivotal phase as the first wave of targeted therapies moves through late-stage development. According to DelveInsight’s analysis, the chondrosarcoma market was valued at approximately USD 15 million across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — in 2025. With…

Diabetes care has entered a new era with automated insulin delivery technology, and the artificial pancreas device system market is at the center of this shift. Valued at USD 334.76 million in 2024, the industry is projected to grow at a CAGR of 16.33% between 2025 and 2032, reaching an estimated USD 1,116.86 million by…